520 related articles for article (PubMed ID: 28870957)
1. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
[TBL] [Abstract][Full Text] [Related]
7. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
[TBL] [Abstract][Full Text] [Related]
10. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
11. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
[TBL] [Abstract][Full Text] [Related]
12. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
14. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
15. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
18. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
[TBL] [Abstract][Full Text] [Related]
19. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
